Can one infusion speed recovery from sickle cell lung crisis?

NCT ID NCT06818266

Recruiting now Disease control Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a single dose of tocilizumab, an anti-inflammatory drug, can help children and adults with sickle cell disease recover faster from acute chest syndrome—a serious lung condition. Participants receive either the drug or a placebo, and researchers measure how quickly they can stop needing oxygen or breathing support. The trial aims to enroll 130 people aged 2 and older.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tocilizumab (a drug that reduces inflammation)
What this could lead to: If it works, this could provide a new treatment to help sickle cell patients recover faster from acute chest syndrome, a serious lung complication.
What could go wrong: This is a Phase 3 trial, but it is still early to know if tocilizumab will work better than standard care. There are risks like infections or allergic reactions from the drug.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE CHEST SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute chest syndrome sickle cell disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE CHEST SYNDROME SICKLE CELL DISEASE

Contacts and locations

Locations

Department of General Pediatrics and Sickle Cell Center, Necker-Enfants malades Hospital
RECRUITING

Paris, 75015, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.